BMRN BioMarin Pharmaceutical Inc.

90.00
-1  -1%
Previous Close 90.90
Open 90.97
Price To book 5.67
Market Cap 15.56B
Shares 172,866,000
Volume 890,862
Short Ratio 6.83
Av. Daily Volume 1,109,350

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released July 2016. Update due in December 2016. Phase 2b to be initiated 2H 2017.
BMN 270
Hemophilia A
Phase 2 updated data released October 2016. Phase 3 trial to be initiated end of 2016.
Vosoritide
Achondroplasia
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. BLA filing to be filed 2Q 2017.
Pegvaliase
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
  2. BIOMARIN PHARMACEUTICAL INC Financials
  3. Coverage initiated on BioMarin Pharm by Instinet
  4. Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval
  5. Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
  6. BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017
  7. BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017
  8. Blog Coverage Cempra Announced Positive Results from the Phase-III Study for the Treatment of Acute Bacterial Skin and Skin Structure Infections
  9. BIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report
  10. BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
  11. BioMarin 'Attractive' M&A Target Despite Growing Losses: RBC
  12. BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
  13. Edited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT
  14. BioMarin reports 4Q loss
  15. BioMarin reports 4Q loss
  16. BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  17. BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
  18. Q4 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
  19. 3 Biotech Stocks You May Be Overlooking
  20. Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More